
Opinion|Videos|July 9, 2024
The Impact of Payer Coverage and Reimbursement on Biosimilars
Dr. Cannon leads a conversation navigating the impact of payer coverage on the uptake of biosimilars.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are payer coverage and reimbursement policies impacting the uptake of biosimilars? What have you observed in your practice?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
2
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
3
'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum
4
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
5












































